{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:36:15Z","timestamp":1790660175642,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Key Research and Development Program of China","award":["2022YFC2304800"],"award-info":[{"award-number":["2022YFC2304800"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Integrase strand transfer inhibitor (INSTI)-based antiretroviral therapy (ART) is recommended for HIV treatment but has been associated with metabolic adverse effects. However, real-world longitudinal data on these metabolic changes remain limited. This study aimed to characterize weight gain, dyslipidemia, and hepatic steatosis in ART-na\u00efve people living with HIV (PLWH) initiating INSTI-based versus efavirenz (EFV)-based therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This prospective cohort study enrolled 772 participants at Nanfang Hospital, Southern Medical University from 2020 to 2023. Participants were categorized into 3 groups: EFV\/tenofovir disoproxil fumarate (TDF)\/lamivudine (3TC) (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009389); elvitegravir\/cobicistat (EVG\/c)\/tenofovir alafenamide (TAF)\/emtricitabine (FTC) or bictegravir (BIC)\/TAF\/FTC (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009168); and dolutegravir (DTG)\/3TC or DTG\/3TC\/TDF (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009215). Metabolic parameters\u2014including body mass index (BMI), lipids, and hepatic steatosis assessed via controlled attenuation parameter (CAP)\u2014were evaluated at baseline, 6, 12, and 24 months using generalized estimating equations.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      At 24 months, INSTI-based regimens were associated with significantly higher BMI compared to EFV\/TDF\/3TC (all\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001), with no difference between INSTI subtypes. All groups showed early increases in triglycerides (TG) and total cholesterol (TC) that stabilized after 12 months; TG and TC levels at 24 months did not differ significantly between TAF-containing INSTI regimens and other groups. The prevalence of hepatic steatosis (CAP\u2009\u2265\u2009238 dB\/m) peaked at 31.2% at year 1 and declined to 28.8% at year 2. Multivariate analysis identified higher BMI (OR 1.55, 95% CI 1.44\u20131.67;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), elevated TG (OR 1.44, 95% CI 1.22\u20131.70;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), and elevated LDL-C (OR 1.90, 95% CI 1.21\u20132.98;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.005) as independent risk factors.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>INSTI-based ART was associated with sustained weight gain but did not worsen long-term dyslipidemia compared to an EFV-based regimen in a real-world setting. Hepatic steatosis correlated with metabolic parameters rather than INSTI exposure.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-026-12553-x","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T01:54:58Z","timestamp":1768355698000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Longitudinal analysis of metabolic changes in people with HIV on integrase inhibitor-based versus efavirenz-based therapy: a prospective real-world cohort study in China"],"prefix":"10.1186","volume":"26","author":[{"given":"Mingzhu","family":"Tao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muye","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaohang","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuwen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,14]]},"reference":[{"issue":"5","key":"12553_CR1","doi-asserted-by":"publisher","first-page":"e295","DOI":"10.1016\/s2352-3018(23)00028-0","volume":"10","author":"A Trickey","year":"2023","unstructured":"Trickey A, Sabin CA, Burkholder G, Crane H, d\u2019Arminio Monforte A, Egger M, et al. Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North america: a collaborative analysis of cohort studies. Lancet HIV. 2023;10(5):e295\u2013307. https:\/\/doi.org\/10.1016\/s2352-3018(23)00028-0.","journal-title":"Lancet HIV"},{"issue":"6","key":"12553_CR2","doi-asserted-by":"publisher","first-page":"e416","DOI":"10.1016\/s2352-3018(25)00032-3","volume":"12","author":"G Li","year":"2025","unstructured":"Li G, Wong VW-S, Chan RS-M, Sin DM-C, Chu W, Wong V, et al. Lifestyle modification programme for people living with HIV with metabolic dysfunction-associated steatotic liver disease: a randomised controlled trial. Lancet HIV. 2025;12(6):e416\u201327. https:\/\/doi.org\/10.1016\/s2352-3018(25)00032-3.","journal-title":"Lancet HIV"},{"issue":"21","key":"12553_CR3","doi-asserted-by":"publisher","first-page":"12020","DOI":"10.3390\/ijms222112020","volume":"22","author":"J Mohan","year":"2021","unstructured":"Mohan J, Ghazi T, Chuturgoon AA. A critical review of the biochemical mechanisms and epigenetic modifications in HIV- and antiretroviral-induced metabolic syndrome. Int J Mol Sci. 2021;22(21):12020. https:\/\/doi.org\/10.3390\/ijms222112020.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"12553_CR4","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41572-020-0181-1","volume":"6","author":"JR Koethe","year":"2020","unstructured":"Koethe JR, Lagathu C, Lake JE, Domingo P, Calmy A, Falutz J, et al. HIV and antiretroviral therapy-related fat alterations. Nat Rev Dis Primers. 2020;6(1):48. https:\/\/doi.org\/10.1038\/s41572-020-0181-1.","journal-title":"Nat Rev Dis Primers"},{"issue":"16","key":"12553_CR5","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1007\/s40265-020-01379-9","volume":"80","author":"KK Scarsi","year":"2020","unstructured":"Scarsi KK, Havens JP, Podany AT, Avedissian SN, Fletcher CV. HIV-1 integrase inhibitors: a comparative review of efficacy and safety. Drugs. 2020;80(16):1649\u201376. https:\/\/doi.org\/10.1007\/s40265-020-01379-9.","journal-title":"Drugs"},{"issue":"9","key":"12553_CR6","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1056\/nejmoa1902824","volume":"381","author":"WDF Venter","year":"2019","unstructured":"Venter WDF, Moorhouse M, Sokhela S, Fairlie L, Mashabane N, Masenya M, et al. Dolutegravir plus two different prodrugs of Tenofovir to treat HIV. N Engl J Med. 2019;381(9):803\u201315. https:\/\/doi.org\/10.1056\/nejmoa1902824.","journal-title":"N Engl J Med"},{"issue":"12","key":"12553_CR7","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.3390\/v15122432","volume":"15","author":"M Bia\u0142y","year":"2023","unstructured":"Bia\u0142y M, Czarnecki M, Inglot M. Impact of combination antiretroviral treatment on liver metabolic health in HIV-infected persons. Viruses. 2023;15(12):2432. https:\/\/doi.org\/10.3390\/v15122432.","journal-title":"Viruses"},{"issue":"9","key":"12553_CR8","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1097\/qad.0000000000003903","volume":"38","author":"G Guaraldi","year":"2024","unstructured":"Guaraldi G, Milic J, Renzetti S, Motta F, Cinque F, Bischoff J, et al. The effect of weight gain and metabolic dysfunction-associated steatotic liver disease on liver fibrosis progression and regression in people with HIV. AIDS. 2024;38(9):1323\u201332. https:\/\/doi.org\/10.1097\/qad.0000000000003903.","journal-title":"AIDS"},{"issue":"12","key":"12553_CR9","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1097\/qad.0000000000003289","volume":"36","author":"J Milic","year":"2022","unstructured":"Milic J, Renzetti S, Ferrari D, Barbieri S, Menozzi M, Carli F, et al. Relationship between weight gain and insulin resistance in people living with HIV switching to integrase strand transfer inhibitors-based regimens. AIDS. 2022;36(12):1643\u201353. https:\/\/doi.org\/10.1097\/qad.0000000000003289.","journal-title":"AIDS"},{"issue":"4","key":"12553_CR10","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1093\/cid\/ciae191","volume":"79","author":"DA Wohl","year":"2024","unstructured":"Wohl DA, Koethe JR, Sax PE, McComsey GA, Kuritzkes DR, Moyle G, et al. Antiretrovirals and weight change: weighing the evidence. Clin Infect Dis. 2024;79(4):999\u20131005. https:\/\/doi.org\/10.1093\/cid\/ciae191.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"12553_CR11","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3803\/enm.2019.34.2.95","volume":"34","author":"D Zaid","year":"2019","unstructured":"Zaid D, Greenman Y. Human immunodeficiency virus infection and the endocrine system. Endocrinol Metab. 2019;34(2):95. https:\/\/doi.org\/10.3803\/enm.2019.34.2.95.","journal-title":"Endocrinol Metab"},{"issue":"6","key":"12553_CR12","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s11904-024-00708-x","volume":"21","author":"S Savinelli","year":"2024","unstructured":"Savinelli S, Newman E, Mallon PWG. Metabolic complications associated with use of integrase strand transfer inhibitors (InSTI) for the treatment of HIV-1 infection: focus on weight changes, lipids, glucose and bone metabolism. Curr HIV\/AIDS Rep. 2024;21(6):293\u2013308. https:\/\/doi.org\/10.1007\/s11904-024-00708-x.","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"1","key":"12553_CR13","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s12967-025-06168-0","volume":"23","author":"L-Y Wan","year":"2025","unstructured":"Wan L-Y, Lam SM, Huang H-H, Cao W-J, Cao X-Y, Li X-M, et al. Multi-omics dissection of metabolic dysregulation associated with immune recovery in people living with HIV-1. J Transl Med. 2025;23(1):143. https:\/\/doi.org\/10.1186\/s12967-025-06168-0.","journal-title":"J Transl Med"},{"issue":"1","key":"12553_CR14","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1001\/jama.2022.22246","volume":"329","author":"RT Gandhi","year":"2023","unstructured":"Gandhi RT, Bedimo R, Hoy JF, Landovitz RJ, Smith DM, Eaton EF, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the international antiviral society\u2013USA panel. JAMA. 2023;329(1):63. https:\/\/doi.org\/10.1001\/jama.2022.22246.","journal-title":"JAMA"},{"issue":"4","key":"12553_CR15","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1097\/qad.0000000000004085","volume":"39","author":"M Weisser","year":"2025","unstructured":"Weisser M, Mapesi H, Vanobberghen F, Okuma J, Eichenberger A, Wilson HI, et al. Body weight changes in people with HIV starting dolutegravir versus efavirenz-based regimens in a large cohort in rural Tanzania. AIDS. 2025;39(4):362\u201372. https:\/\/doi.org\/10.1097\/qad.0000000000004085.","journal-title":"AIDS"},{"key":"12553_CR16","doi-asserted-by":"publisher","unstructured":"Garc\u00eda-Ruiz de Morales AG, Su\u00e1rez Robles M, P\u00e9rez-El\u00edas MJ, Negredo E, Alcam\u00ed J, G\u00f3mez Rodr\u00edguez CE, et al. Metabolic complications after initiating BIC\/FTC\/TAF versus DTG\u2009+\u20093TC in ART-naive adults with human immunodeficiency virus (HIV): a multicenter prospective cohort study. Clin Infect Dis. 2025;ciae645. https:\/\/doi.org\/10.1093\/cid\/ciae645.","DOI":"10.1093\/cid\/ciae645"},{"issue":"2","key":"12553_CR17","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1093\/cid\/ciad545","volume":"78","author":"SH Bares","year":"2023","unstructured":"Bares SH, Wu X, Tassiopoulos K, Lake JE, Koletar SL, Kalayjian R, et al. Weight gain after antiretroviral therapy initiation and subsequent risk of metabolic and cardiovascular disease. Clin Infect Dis. 2023;78(2):395\u2013401. https:\/\/doi.org\/10.1093\/cid\/ciad545.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"12553_CR18","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1093\/cid\/ciz999","volume":"71","author":"PE Sax","year":"2020","unstructured":"Sax PE, Erlandson KM, Lake JE, McComsey GA, Orkin C, Esser S, et al. Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials. Clin Infect Dis. 2020;71(6):1379\u201389. https:\/\/doi.org\/10.1093\/cid\/ciz999.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"12553_CR19","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1097\/coh.0000000000000671","volume":"16","author":"S Shah","year":"2021","unstructured":"Shah S, Hill A. Risks of metabolic syndrome and diabetes with integrase inhibitor-based therapy: republication. Curr Opin HIV AIDS. 2021;16(2):106\u201314. https:\/\/doi.org\/10.1097\/coh.0000000000000671.","journal-title":"Curr Opin HIV AIDS"},{"issue":"5","key":"12553_CR20","doi-asserted-by":"publisher","first-page":"ofab077","DOI":"10.1093\/ofid\/ofab077","volume":"8","author":"NS Nolan","year":"2021","unstructured":"Nolan NS, Adamson S, Reeds D, O\u2019Halloran JA. Bictegravir-based antiretroviral therapy-associated accelerated hyperglycemia and diabetes mellitus. Open Forum Infect Dis. 2021;8(5):ofab077. https:\/\/doi.org\/10.1093\/ofid\/ofab077.","journal-title":"Open Forum Infect Dis"},{"issue":"10","key":"12553_CR21","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1097\/qad.0000000000002930","volume":"35","author":"K McCann","year":"2021","unstructured":"McCann K, Shah S, Hindley L, Hill A, Qavi A, Simmons B, et al. Implications of weight gain with newer anti-retrovirals: 10-year predictions of cardiovascular disease and diabetes. AIDS. 2021;35(10):1657\u201365. https:\/\/doi.org\/10.1097\/qad.0000000000002930.","journal-title":"AIDS"},{"issue":"7","key":"12553_CR22","doi-asserted-by":"publisher","first-page":"e2234","DOI":"10.1093\/cid\/ciaa1403","volume":"73","author":"PF Rebeiro","year":"2021","unstructured":"Rebeiro PF, Jenkins CA, Bian A, Lake JE, Bourgi K, Moore RD, et al. Risk of incident diabetes mellitus, weight gain, and their relationships with integrase inhibitor\u2013based initial antiretroviral therapy among persons with human immunodeficiency virus in the united States and Canada. Clin Infect Dis. 2021;73(7):e2234\u201342. https:\/\/doi.org\/10.1093\/cid\/ciaa1403.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"12553_CR23","doi-asserted-by":"publisher","first-page":"e355","DOI":"10.1016\/s2352-3018(19)30077-3","volume":"6","author":"DA Wohl","year":"2019","unstructured":"Wohl DA, Yazdanpanah Y, Baumgarten A, Clarke A, Thompson MA, Brinson C, et al. Bictegravir combined with emtricitabine and Tenofovir Alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet HIV. 2019;6(6):e355\u201363. https:\/\/doi.org\/10.1016\/s2352-3018(19)30077-3.","journal-title":"Lancet HIV"},{"issue":"1","key":"12553_CR24","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1097\/qad.0000000000003063","volume":"36","author":"L Calza","year":"2022","unstructured":"Calza L, Borderi M, Colangeli V, Miani T, Nuti B, Bon I, et al. Weight gain in treatment-naive HIV-1 infected patients starting abacavir\/lamivudine\/dolutegravir or tenofovir alafenamide\/emtricitabine\/bictegravir. AIDS. 2022;36(1):153\u20135. https:\/\/doi.org\/10.1097\/qad.0000000000003063.","journal-title":"AIDS"},{"issue":"1","key":"12553_CR25","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12944-023-01786-3","volume":"22","author":"X-d Yu","year":"2023","unstructured":"Yu X-d, Huang H, Jiao Y, Li J, Fan X, Zhang D, et al. Incidence and risk factors of hypertriglyceridemia in males with human immunodeficiency virus who are treated with combination antiretroviral therapy: a retrospective cohort study. Lipids Health Dis. 2023;22(1):27. https:\/\/doi.org\/10.1186\/s12944-023-01786-3.","journal-title":"Lipids Health Dis"},{"issue":"1","key":"12553_CR26","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1186\/s12944-024-02224-8","volume":"23","author":"Y Xu","year":"2024","unstructured":"Xu Y, Qi B, Wu X, Lu C, Chen P, Wang D, et al. Interaction between antiretroviral therapy regimens and body mass index on triglyceride levels in people living with HIV: a cross-sectional and longitudinal study. Lipids Health Dis. 2024;23(1):232. https:\/\/doi.org\/10.1186\/s12944-024-02224-8.","journal-title":"Lipids Health Dis"},{"issue":"12","key":"12553_CR27","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1089\/apc.2019.0236","volume":"33","author":"KJ Kauppinen","year":"2019","unstructured":"Kauppinen KJ, Kivel\u00e4 P, Sutinen J. Switching from Tenofovir disoproxil fumarate to Tenofovir Alafenamide significantly worsens the lipid profile in a real-world setting. AIDS Patient Care STDS. 2019;33(12):500\u20136. https:\/\/doi.org\/10.1089\/apc.2019.0236.","journal-title":"AIDS Patient Care STDS"},{"issue":"9","key":"12553_CR28","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1111\/hiv.13659","volume":"25","author":"C Busca-Arenzana","year":"2024","unstructured":"Busca-Arenzana C, Ortega\u2010Gonz\u00e1lez D, D\u00edaz\u2010Almir\u00f3n M, Montes ML, Martin\u2010Carbonero L, Mican R, et al. Metabolic effects of switching to biktarvy (B\/F\/TAF) in patients with HIV\u20101 treated with antiretroviral regimens that do not include Tenofovir disoproxil fumarate (TDF) or Tenofovir Alafenamide (TAF): the metabic study. HIV Med. 2024;25(9):1030\u20139. https:\/\/doi.org\/10.1111\/hiv.13659.","journal-title":"HIV Med"},{"issue":"1","key":"12553_CR29","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1186\/s12879-025-10455-y","volume":"25","author":"J Wei","year":"2025","unstructured":"Wei J, Hui W, Fang Y, Jia H, Yang Y, Zhang T, et al. The prevalence of nonalcoholic fatty liver disease in people living with HIV: a systematic review and meta-analysis. BMC Infect Dis. 2025;25(1):239. https:\/\/doi.org\/10.1186\/s12879-025-10455-y.","journal-title":"BMC Infect Dis"},{"issue":"7","key":"12553_CR30","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1016\/j.cgh.2023.01.001","volume":"21","author":"M Kalligeros","year":"2023","unstructured":"Kalligeros M, Vassilopoulos A, Shehadeh F, Vassilopoulos S, Lazaridou I, Mylonakis E, et al. Prevalence and characteristics of nonalcoholic fatty liver disease and fibrosis in people living with HIV monoinfection: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2023;21(7):1708\u201322. https:\/\/doi.org\/10.1016\/j.cgh.2023.01.001.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"12553_CR31","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.cgh.2022.03.048","volume":"21","author":"M Lemoine","year":"2023","unstructured":"Lemoine M, Assoumou L, Girard P-M, Valantin MA, Katlama C, De Wit S, et al. Screening HIV patients at risk for NAFLD using MRI-PDFF and transient elastography: a European multicenter prospective study. Clin Gastroenterol Hepatol. 2023;21(3):713\u2013e223. https:\/\/doi.org\/10.1016\/j.cgh.2022.03.048.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"12553_CR32","doi-asserted-by":"publisher","first-page":"e2184","DOI":"10.1093\/cid\/ciaa1302","volume":"73","author":"JB Maurice","year":"2020","unstructured":"Maurice JB, Goldin R, Hall A, Price JC, Sebastiani G, Morse CG, et al. Increased body mass index and type 2 diabetes are the main predictors of nonalcoholic fatty liver disease and advanced fibrosis in liver biopsies of patients with human immunodeficiency virus monoinfection. Clin Infect Dis. 2020;73(7):e2184\u201393. https:\/\/doi.org\/10.1093\/cid\/ciaa1302.","journal-title":"Clin Infect Dis"},{"key":"12553_CR33","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ejim.2023.01.028","volume":"110","author":"J Navarro","year":"2023","unstructured":"Navarro J, Curran A, Ravent\u00f3s B, Garc\u00eda J, Suanzes P, Descalzo V, et al. Prevalence of non-alcoholic fatty liver disease in a multicentre cohort of people living with HIV in Spain. Eur J Intern Med. 2023;110:54\u201361. https:\/\/doi.org\/10.1016\/j.ejim.2023.01.028.","journal-title":"Eur J Intern Med"},{"issue":"12","key":"12553_CR34","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1111\/hiv.13730","volume":"25","author":"M Laguno","year":"2024","unstructured":"Laguno M, de Lazzari E, Berrocal L, Inciarte A, Mart\u00ednez-Rebollar M, de la Mora L, et al. Burden of liver steatosis and liver fibrosis in a large cohort of people living with HIV. HIV Med. 2024;25(12):1308\u201324. https:\/\/doi.org\/10.1111\/hiv.13730.","journal-title":"HIV Med"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-12553-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-12553-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-12553-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T14:59:05Z","timestamp":1770649145000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-12553-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,14]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["12553"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-12553-x","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,14]]},"assertion":[{"value":"24 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Nanfang Hospital, Southern Medical University, and written consent was obtained from all participants. The ethic number: NFEC-2021-448. The study was conducted in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"302"}}